Vinnova is going to establish a new innovation cluster

Vinnova, the Swedish Agency for Innovation Systems, has been commissioned by the government to establish a national innovation cluster for advanced medicines.

ARM-D – Vill du spara plats i din maskin?

Nya modulära regulatorn ARM-D ger ett ytterst kompakt montage för samtidig reglering av flera tryck.

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

Automated dispensing of liquids

Have a look at how you can do easier and faster dispensing on the fly adapted to your needs

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

This is the future location of the new national innovation cluster

Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish gov...

Anna Törner: To kill your darlings

Förhoppningarna var höga när Anna Törner och hennes kollega startade en studie om ett kosttillskott som verkade vara overkligt bra. "Entusiastiskt drömde vi om ...

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Engage with your CMO early

Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.

Marie Gårdmark: Do EMA and FDA talk to each other?

Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.

Krönika: Collaboration across borders

Swedish and Danish Life Science – are there still untapped synergies?

not be better. A one-day conference on ongoing collaborations, new directions and required future investment will held on April 2nd at Medicon Village in Lund.

Brexit looking back and looking forward

More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards...

Anna Törner: You won’t find this many Concorde projects anywhere else

"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...

Överraskande studieresultat om testosteron – Minskade inte risk för frakturer

Det är känt att behandling med testosteron ökar bentäthet och benkvalitet. Men nu tyder en studie på att tillförsel av det manliga könshormonet ändå inte medför...

Egetis bekräftar budsamtal

Den svenska läkemedelsutvecklaren Egetis Therapeutics för diskussioner om ett potentiellt bud på bolaget. Det bekräftar företaget i en kommentar till ihärdiga r...

Column: ”Life as a F1 race”

"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing wr...

Extensive agreements signed at Scilifelab

Four agreements were signed between Swedish and Dutch life science players in connection with the Dutch state visit earlier this month.

Swedish Healthtech Company 1928 Pushing Forward

The full service analytics platform is expanding the business.

Webinar: How to Plan And Analyze a Real-World Evidence Study

This webinar is for drug developers who want to understand the basic ideas of analyzing an RWE study, as well as avoiding the most common pitfalls.

Egetis lägger ned buddiskussionerna

Svenska läkemedelsutvecklaren Egetis Therapeutics har gått ut med att diskussionerna om ett potentiellt förvärv av företaget nu har lagts ner.

Study: Semaglutide tablet produces weight loss

The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.

Drug development creates new challenges for regulators